Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

Juan, Óscar; Vidal, J.; Gisbert, R.; Muñoz, J.; Maciá, Sonia; Gómez-Codina, José

doi:10.1007/s12094-013-1128-8

Cited by 53 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results contrast with the majority of reported data in NSCLC which shows that patients treated with chemotherapy had worse OS and PFS with a higher CTC number [18,31,32,33,34,35,36]. Only one study by Juan et al [37] reported similar findings in a group of advanced NSCLC treated with docetaxel and gemcitabine. In particular, the authors found a longer median PFS and OS in patients with an increased CTC number (CTCs ≥ 2/7.5 mL) [37].…”

Section: Discussioncontrasting

confidence: 99%

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Coco

Alama

Vanni

et al. 2017

IJMS

View full text Add to dashboard Cite

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the prognostic role of cfDNA and CTCs, in separate and joint analyses, in NSCLC patients receiving first line chemotherapy. Seventy-three patients with advanced NSCLC were enrolled in this study. CfDNA and CTC were analyzed at baseline and after two cycles of chemotherapy. Plasma cfDNA quantification was performed by quantitative PCR (qPCR) whereas CTCs were isolated by the ScreenCell Cyto (ScreenCell, Paris, France) device and enumerated according to malignant features. Patients with baseline cfDNA higher than the median value (96.3 hTERT copy number) had a significantly worse overall survival (OS) and double the risk of death (hazard ratio (HR): 2.14; 95% confidence limits (CL) = 1.24–3.68; p-value = 0.006). Conversely, an inverse relationship between CTC median baseline number (6 CTC/3 mL of blood) and OS was observed. In addition, we found that in patients reporting stable disease (SD), the baseline cfDNA and CTCs were able to discriminate patients at high risk of poor survival. cfDNA demonstrated a more reliable biomarker than CTCs in the overall population. In the subgroup of SD patients, both biomarkers identified patients at high risk of poor prognosis who might deserve additional/alternative therapeutic interventions.

show abstract

Section: Discussioncontrasting

confidence: 99%

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Coco

Alama

Vanni

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

“…For example, in SCLC the total numbers of CTCs were significantly decreased following a single dose of chemotherapy (166,167). Similar results were observed in patients with NSCLC (5,(168)(169)(170). In contrast, an increase in CTC numbers is indicative of failure to respond to therapy.…”

Section: Treatment Response and Mechanisms Of Resistancesupporting

confidence: 57%

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Mohan¹,

Chemi²,

Brady³

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

“…CTC assessment with the CellSearch system was not prognostic in a study that analyzed 37 fragile patients (36). In fact, no significant association between CTC count and both PFS and OS was observed using a threshold of two CTC to discriminate between high-and low-CTC count.…”

Section: Prognostic and Predictive Value Of Ctc In Advanced Nsclcmentioning

confidence: 91%

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Several different studies have addressed the role of the circulating tumor cells (CTC) in nonsmall-cell lung cancer (NSCLC). In particular, the potential of CTC analysis in the early diagnosis of NSCLC and in the prediction of the outcome of patients with early and advanced NSCLC have been explored. A major limit of these studies is that they used different techniques for CTC isolation and enumeration, they employed different thresholds to discriminate between high-and low-risk patients, and they enrolled heterogeneous and often small cohort of patients. Nevertheless, the results of many studies are concordant in indicating a correlation between high CTC count and poor prognosis in both early and advanced NSCLC. The reduction of CTC number following treatment might also represent an important indicator of sensitivity to therapy in patients with metastatic disease. Preliminary data also suggest the potential for CTC analysis in the early diagnosis of NSCLC in high-risk individuals. However, these findings need to be confirmed in large prospective trials in order to be transferred to the clinical practice.The molecular profiling of single CTC in NSCLC might provide important information on tumor biology and on the mechanisms involved in tumor dissemination and in acquired resistance to targeted therapies. In this respect, xenografts derived from CTC might represent a valuable tool to investigate these phenomena and to develop novel therapeutic strategies.

show abstract

Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine

Abstract: CTCs ≥2 at baseline were detected only in 24 % of this group of patients with advanced NSCLC and poor performance status. No significant differences in PFS and OS between patients with or without CTCs at baseline were observed.

Cited by 53 publications

References 29 publications

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Contact Info

Product

Resources

About